Brief: Oncolytics Biotech Achieves Success Criteria For Efficacy In The Pancreatic Cancer Cohort Of Goblet
28/06/2022 12:06
June 28 (Reuters) - Oncolytics Biotech Inc ONC.TO :
* ONCOLYTICS BIOTECH® ACHIEVES SUCCESS CRITERIA FOR EFFICACY
IN
THE PANCREATIC CANCER COHORT OF GOBLET
* ONCOLYTICS BIOTECH INC - PARTIAL RESPONSES ACHIEVED IN ALL
PATIENTS IN COHORT'S 1B PORTION
* ONCOLYTICS BIOTECH INC - EXPANSION CRITERIA FOR PANCREATIC
CANCER COHORT HAS BEEN MET TO ALLOW FOR ADDITIONAL PATIENT
ENROLLMENT
* ONCOLYTICS BIOTECH - DATA SUGGEST PELAREOREP
SYNERGISTICALLY
COMBINES WITH CHEMOTHERAPY AND CHECKPOINT INHIBITION IN A HIGHLY
CHALLENGING INDICATION
Source text for Eikon: ID:nPresnXMwa
Further company coverage: ONC.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Oncolytics Biotech
See all newsBrief: Oncolytics Biotech Files For Mixed Shelf Offering Of Up To $150 Million
Brief: Oncolytics Biotech® Announces Voluntary Delisting From The Toronto Stock Exchange
Advisory: Alert on global oncology breakthroughs tagged to multiple pharma firms withdrawn
Brief: Oncolytics Biotech® Appoints Former Ambrx Executive As Chief Business Officer
Brief: Oncolytics Biotech Appoints Former Ambrx Executive As Chief Business Officer